- Home
- HBANL vs VCEL Comparison
HBANL vs VCEL Comparison
Compare HBANL & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBANL
- VCEL
- Stock Information
- Founded
- HBANL N/A
- VCEL 1989
- Country
- HBANL United States
- VCEL United States
- Employees
- HBANL 20092
- VCEL N/A
- Industry
- HBANL Major Banks
- VCEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HBANL Finance
- VCEL Health Care
- Exchange
- HBANL Nasdaq
- VCEL Nasdaq
- Market Cap
- HBANL N/A
- VCEL 2.1B
- IPO Year
- HBANL N/A
- VCEL 1997
- Fundamental
- Price
- HBANL $25.17
- VCEL $42.55
- Analyst Decision
- HBANL
- VCEL Strong Buy
- Analyst Count
- HBANL 0
- VCEL 8
- Target Price
- HBANL N/A
- VCEL $62.00
- AVG Volume (30 Days)
- HBANL N/A
- VCEL 439.0K
- Earning Date
- HBANL N/A
- VCEL 07-31-2025
- Dividend Yield
- HBANL N/A
- VCEL N/A
- EPS Growth
- HBANL N/A
- VCEL 521.85
- EPS
- HBANL N/A
- VCEL 0.05
- Revenue
- HBANL N/A
- VCEL $238,541,000.00
- Revenue This Year
- HBANL N/A
- VCEL $23.03
- Revenue Next Year
- HBANL N/A
- VCEL $24.52
- P/E Ratio
- HBANL N/A
- VCEL $724.21
- Revenue Growth
- HBANL N/A
- VCEL 14.80
- 52 Week Low
- HBANL N/A
- VCEL $37.39
- 52 Week High
- HBANL N/A
- VCEL $63.00
- Technical
- Relative Strength Index (RSI)
- HBANL 53.60
- VCEL 51.57
- Support Level
- HBANL $25.10
- VCEL $40.53
- Resistance Level
- HBANL $25.36
- VCEL $43.51
- Average True Range (ATR)
- HBANL 0.17
- VCEL 1.77
- MACD
- HBANL 0.04
- VCEL -0.08
- Stochastic Oscillator
- HBANL 64.81
- VCEL 42.62
About HBANL Huntington Bancshares Incorporated Depositary Shares Each Representing a 1/40th Interest in a Share of 6.875% Series J Non-Cumulative Perpetual Preferred Stock
Huntington is a regional US bank with around $200 billion in assets (as of 2024) and has a large presence, particularly in the Midwestern market. It offers a full suite of consumer deposit and lending services, along with commercial services focused on payments, investment management, capital markets, equipment financing, treasury management, and other common banking services.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.